OncoHub.ai
An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.
Indication: HER2+, RAS/RAF wild-type, chemotherapy-refractory mCRC
Key finding: Median PFS (IRC) 5.5 mo (95% CI 4.8–6.7) vs 2.8 mo (2.2–4.2); HR 0.33 (95% CI 0.21–0.53; 1-sided p<0.0001); ORR 40.7% vs 4.5%; OS HR 0.77 (0.35–1.73); G≥3 TRAE 48.8% vs 50.0%; 2 treatment-related deaths in the T-rezetecan arm.
Clinical relevance: Establishes a HER2-targeted ADC as superior to standard 3L options in HER2+ mCRC.
Source: ASCO Abstract 3505
Indication: Resected stage I–IV colorectal cancer
Key finding: In the "decreasing but detectable" subgroup, longer adjuvant chemotherapy improved DFS (median 5.9 vs 1.7 mo; HR 3.64, p=0.012); no benefit in the sustained-negative, clearance, or rising-ctDNA subgroups.
Clinical relevance: ctDNA trajectory can guide adjuvant treatment duration.
Source: ASCO Abstract 3501
Indication: dMMR/MSI-H colorectal cancer, non-operative management
Key finding: 3-yr DFS observation 96.4% vs maintenance 98.4% (p=0.55); 3-yr OS 100% vs 98.4% (p=0.34); G3 irAE 3.0% vs 11.1% (p=0.091).
Clinical relevance: Observation may be adequate after complete response; maintenance adds toxicity without clear benefit.
Source: ASCO Abstract 3502
Indication: Pretreated MSS BRAF V600E mCRC
Key finding: Median PFS 5.8 vs 6.3 mo (HR 1.10, p=0.64); ORR 35% vs 32%; G3-4 TRAE 54% vs 36%; adding nivolumab did not improve outcomes.
Clinical relevance: No role for adding nivolumab to encorafenib+cetuximab in MSS BRAF V600E mCRC.
Source: ASCO Abstract 3504
Indication: Stage III / high-risk stage II colon cancer
Key finding: A structured exercise program (SEP) was dominant over health-education materials: −$179 cost, +0.06 LYs, +0.10 QALYs; dominant in 49% of bootstrap samples; 79% under a $50K/QALY threshold.
Clinical relevance: Exercise is a cost-effective adjunct in colon cancer.
Source: ASCO Abstract 3507
Indication: HPV+ oropharyngeal cancer (OPC)
Key finding: 5-yr OS 97% in both the 30 Gy and 70 Gy cohorts; 5-yr local failure 2.2% vs 1.9%; distant failure 1.3% vs 7.5% (p=0.004); ~75% received de-escalated 30 Gy.
Clinical relevance: Hypoxia-PET selection enables major RT de-escalation without compromising control.
Source: ASCO Abstract 103
Indication: Resectable esophageal adenocarcinoma (EAC)
Key finding: Pre-surgery PRO favored FLOT (global health +6.3, physical functioning +7.7, less fatigue/dyspnea/eating problems); sensory neuropathy was worse with FLOT at all timepoints.
Clinical relevance: FLOT offers a better pre-surgical quality-of-life profile aside from neuropathy.
Source: ASCO Abstract 105
Indication: Malignant ascites
Key finding: Median puncture-free survival 87.59 vs 49.96 days (HR 0.57, p=0.0003); time to next puncture 186.7 vs 55.1 days; OS comparable; G≥3 TEAE 70.4% vs 51.9%; one G1 CRS.
Clinical relevance: Meaningful control of malignant ascites with intraperitoneal bispecific therapy.
Source: ASCO Abstract 104
Indication: BRAF V600E mCRC, 1L
Key finding: 1L encorafenib + cetuximab + FOLFIRI PFS/OS analyses; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA3503
Indication: Stage II colon cancer
Key finding: ctDNA-based adjuvant decision-making; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA3500
Indication: Resectable CRC liver metastases (PUMP) · Stage III CRC adjuvant aspirin (EPISODE-III/JCOG1503C)
Key finding: Adjuvant hepatic-arterial-infusion floxuridine RCT (PUMP) and adjuvant aspirin RCT (EPISODE-III); full text was not available in the source for either.
Clinical relevance: Unclear; must be verified against the full texts.
Source: ASCO Abstract LBA3506 / LBA3508
Indication: Early-stage node-negative OSCC with intermediate-risk features
Key finding: 3-yr LRFS 89.2% vs 80.9% (HR 0.52, 95% CI 0.30–0.91; p=0.02 ITT); per-protocol 91.1% vs 80.9% (HR 0.43); no significant OS/DFS difference; oral tongue derived higher benefit.
Clinical relevance: Adjuvant RT improves locoregional control in intermediate-risk early OSCC.
Source: ASCO Abstract 6000
Indication: Resected high-risk HNSCC
Key finding: DFS benefit was preserved regardless of unilateral vs bilateral lymph-node dissection (unilateral HR 0.79 [0.50–1.26]; bilateral HR 0.77 [0.57–1.03]); benefit also persisted with >39 nodes removed (HR 0.75 [0.54–1.05]).
Clinical relevance: Nivolumab benefit is independent of the extent of nodal dissection.
Source: ASCO Abstract 6001
Indication: HPV-unrelated R/M HNSCC after ICI + platinum chemotherapy
Key finding: Confirmed ORR 47% (48/102; 95% CI 37–57); median DoR 7.2 mo (5.8–NE); median PFS 6.8 mo (5.2–8.2).
Clinical relevance: Encouraging activity in a refractory HNSCC population.
Source: ASCO Abstract 6008
Indication: Locally advanced nasopharyngeal carcinoma (LA-NPC)
Key finding: 3-yr FFS 85.4% (2-cycle) vs 86.7% (3-cycle); HR 1.11; non-inferiority P=0.0031; less G3-4 neutropenia, leukopenia, and vomiting with 2 cycles.
Clinical relevance: Two induction cycles are non-inferior with less toxicity.
Source: ASCO Abstract 6003
Indication: Locally advanced nasopharyngeal carcinoma
Key finding: 3-yr FFS 85.7% vs 87.6%; HR 1.234 (95% CI 0.744–2.045); non-inferiority p=0.0112; less neutropenia/anorexia/nephrotoxicity with carboplatin.
Clinical relevance: Carboplatin is a viable, better-tolerated alternative to cisplatin in LA-NPC.
Source: ASCO Abstract 6004
Indication: 1L recurrent/metastatic HNSCC
Key finding: ORR 41% (I+P) vs 17% (P); CR 15% vs 4.2%; median PFS 8.1 vs 6.2 mo at a median follow-up of 7.0 mo.
Clinical relevance: Adding ipatasertib enhances response over pembrolizumab alone.
Source: ASCO Abstract 6006
Indication: Locally advanced oral cavity squamous cell carcinoma (OCSCC)
Key finding: 2-yr OS 79.2% vs 70.2% (HR 0.76; p=0.13, n.s.); 2-yr PFS 77.0% vs 68.0% (HR 0.72; p=0.044); G3-4 toxicity 6.9%.
Clinical relevance: A low-cost metronomic adjuvant improved PFS; OS difference not significant.
Source: ASCO Abstract 6002
Indication: R/M HNSCC
Key finding: ORR 35% (2 CR, 5 PR), DCR 45% (9/20); median DoR 332 days; the only AE was injection-site ulcer (40%).
Clinical relevance: Durable responses with a benign safety profile in a small cohort.
Source: ASCO Abstract 2503
Indication: LA-NPC with suboptimal induction response (6005) · Platinum-sensitive R/M HNSCC (LBA6007)
Key finding: Adjuvant sintilimab-capecitabine vs capecitabine (6005), and ultra-low-dose immunotherapy + oral metronomic chemo vs paclitaxel-carboplatin (LBA6007); full text was not available in the source for either.
Clinical relevance: Unclear; must be verified against the full texts.
Source: ASCO Abstract 6005 / LBA6007
Indication: 1L HER2+ metastatic breast cancer
Key finding: Confirmed ORR 82.8% (80% CI 75.2–88.8); median DoR 36.1 mo; median PFS 37.7 mo; 24-mo PFS 75.5%; adjudicated drug-related ILD/pneumonitis 17.5% (G1 n=1, G2 n=8, G3 n=2); 2 treatment-emergent deaths.
Clinical relevance: Deep, durable activity in 1L HER2+ mBC; ILD requires vigilance.
Source: ASCO Abstract 1012
Indication: Stage II-III TNBC
Key finding: pCR 57.5% vs 45.4% (Δ12.2 pp; 95% CI 1.4–22.9; 1-sided P=0.014); CPS≥1 subgroup pCR 69.8% vs 51.9%; CPS<1 37.8% vs 28.1% (n.s.).
Clinical relevance: Adding camrelizumab improves pCR, particularly in CPS≥1 TNBC.
Source: ASCO Abstract 1009
Indication: Node-positive TNBC
Key finding: Preoperative RT + pembrolizumab significantly increased 2-week tumor T-cell infiltration vs pembrolizumab alone; ypN0 rates 73.3% (0 Gy), 88.2% (9 Gy), 78.9% (24 Gy); pCR 66.6%/76.5%/68.4%; upper-quartile TCI 44%/80%/82% (RT cohorts p<0.0001).
Clinical relevance: Low-dose RT can prime immune infiltration; clinical endpoints exploratory.
Source: ASCO Abstract 1011
Indication: Early-stage TNBC
Key finding: Time-of-day of avelumab interacted with immune status: AM-rate × TILs interaction DDFS p=0.008, OS p=0.001; immune-aligned vs misaligned 3-yr OS 95.7% vs 75.2% (by TILs).
Clinical relevance: Hypothesis-generating signal that infusion timing may matter; needs prospective validation.
Source: ASCO Abstract 1010
Indication: HR+/HER2− advanced breast cancer (Asian)
Key finding: Final OS analysis of palbociclib + tamoxifen ± goserelin; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA1018
Indication: Stage IB-IIIA RET fusion-positive NSCLC
Key finding: Primary results report an event-free survival benefit with adjuvant selpercatinib; full statistics were not available in the source.
Clinical relevance: Potentially practice-relevant for adjuvant RET+ NSCLC; verify against the full text.
Source: ASCO Abstract LBA3
Indication: Previously untreated advanced squamous NSCLC
Key finding: Ivonescimab + chemo improved overall survival vs tislelizumab + chemo; full statistics were not available in the source.
Clinical relevance: Potentially practice-changing in squamous NSCLC; verify against the full text.
Source: ASCO Abstract LBA4
Indication: Pediatric/young-adult high-risk B-ALL with persistent end-of-consolidation MRD ≥0.01%
Key finding: 4-yr OS 85% (95% CI 76–90); 3-yr DFS 71% (61–79); 5-yr DFS 64% (53–73) without censoring; MRD-negative at D29 95%, at 3 mo 86%; CRS any 37% (≥G3 2%); ICANS 3% (≥G3 1%).
Clinical relevance: Tisa-cel offers durable remission in very-high-risk pediatric B-ALL.
Source: ASCO Abstract 10000
Indication: Pediatric metastatic rhabdomyosarcoma
Key finding: 5-yr EFS 31.6% (Oberlin >1: 16.2%; ≤1: 61.5%); non-irradiated soft-tissue CR mets had 41% in-site recurrence vs 5.9% with RT.
Clinical relevance: Supports consolidative RT to soft-tissue metastases.
Source: ASCO Abstract 10002
Indication: Anthracycline-related cardiomyopathy in survivors
Key finding: A survivor-specific 8-variant PRS combined with the clinical model outperformed the clinical model alone (AUC 0.70 [0.57–0.82] vs 0.63 [0.50–0.76], p=0.04); adjusted NPV 95.1%.
Clinical relevance: Genetic risk stratification can refine cardiac surveillance.
Source: ASCO Abstract 10005
Indication: Pediatric R/R solid tumors
Key finding: RP2D spartalizumab 4 mg/kg q4w + pazopanib 225 mg/m²/day; 4 DLTs across 3 dose levels; 1 CR, 4 PR, 8 SD among 40 evaluable; signal in osteosarcoma.
Clinical relevance: Early activity signal warranting further study.
Source: ASCO Abstract 10001
Indication: Insomnia + cognitive impairment in survivors
Key finding: CBT-I improved ISI at 9 weeks (MD −2.4, d=0.50) and 6 months (MD −3.5, d=0.72); it mediated 42–65% of cognitive improvement.
Clinical relevance: A scalable intervention improving sleep and cognition in survivors.
Source: ASCO Abstract 10003
Indication: Survivors with prior abdominopelvic/spinal/TBI radiotherapy
Key finding: 12-mo CRC surveillance 32% (patient activation) vs 14% (control) [p=0.003]; PA+PCP 26% vs 14% (p=0.041, did not meet α=0.025).
Clinical relevance: Patient activation improves guideline-concordant surveillance.
Source: ASCO Abstract 10004
Indication: Rare cancers
Key finding: Activity in 24/53 cohorts; median ORR 12% (range 0–75%), CBR 27%; notable cohorts: gestational trophoblastic disease ORR 75%, basal cell carcinoma 35%, bronchoalveolar carcinoma 25%, desmoid 19%; G5 TRAE 1.8%.
Clinical relevance: Dual IO has meaningful activity across several rare tumor types.
Source: ASCO Abstract 2502
Indication: TP53 R175H+ / HLA-A*02:01 advanced solid tumors
Key finding: ORR 47.6% (95% CI 25.7–70.2); DL3 ORR 53.8%; PRs in 5/6 PDAC; no DLTs.
Clinical relevance: Proof of concept for targeting a shared p53 neoantigen, notably in PDAC.
Source: ASCO Abstract 2506
Indication: GPC3+ advanced hepatocellular carcinoma (HCC)
Key finding: At RP2D, confirmed ORR 66.7% (6/9), DCR 88.9% (8/9); median OS 14.4 mo; CRS ≥G3 42.1%; 1 DLT.
Clinical relevance: Promising activity in GPC3+ HCC; CRS management important.
Source: ASCO Abstract 2508
Indication: Treatment-refractory cancers
Key finding: ORR 33% (6/18); PDAC 50% (3/6); peritoneal mesothelioma 100% (2/2); TILScore AUC 0.806 (p=0.041).
Clinical relevance: A biomarker-guided TIL approach with cross-tumor activity.
Source: ASCO Abstract 2505
Indication: Advanced solid tumors
Key finding: ORR 17.3% (13/75); uveal melanoma ORR 33.3% (5/15); RP2 monotherapy confirmed responses 4/21 (19%); median DoR 22.1 mo.
Clinical relevance: Durable responses including in uveal melanoma.
Source: ASCO Abstract 2504
Indication: MAGE-A4/8+ solid tumors
Key finding: Head & neck cORR 25% (2/8) initially, 33% (4/12) after data cutoff; melanoma cORR 29%; squamous NSCLC 1 PR/1 SD/1 PD; CRS G1 24%, G2 11%; no formal MTD reached.
Clinical relevance: An off-the-shelf TCR bispecific with multi-tumor activity.
Source: ASCO Abstract 2507
Indication: PD-1/PD-L1 R/R solid tumors
Key finding: ORR 20% (3/15); biomarker-selected ORR 75% (3/4); DCR 54% at week 12.
Clinical relevance: Early signal, enriched in a biomarker-selected subset.
Source: ASCO Abstract 2501
Indication: Post-anti-PD-1 / MSS-CRC
Key finding: ORR 10–33%; durable clinical benefit 26–57%; median PFS 1.9–7.5 mo across cohorts; ≥G3 TRAE 3%.
Clinical relevance: Early activity including in immunotherapy-resistant settings.
Source: ASCO Abstract 2500
Indication: Cross-cutting (cell & TCR-engager therapies)
Key finding: Across these early-phase cell/TCR programs, cytokine-release events were generally low-grade and manageable (e.g., Ori-C101 CRS ≥G3 42.1% being the notable exception), with no formal MTD reached for several.
Clinical relevance: A maturing safety picture for off-the-shelf and engineered T-cell approaches.
Source: ASCO Abstracts 2504–2508
Indication: Moderately emetogenic chemotherapy CINV
Key finding: Delayed-phase complete response 79.0% vs 61.4% (Δ17.8%; P<0.0001); overall-phase CR 75.6% vs 59.9% (P<0.0001); G≥3 TRAE 1.2% vs 1.4%.
Clinical relevance: A more effective fixed antiemetic combination for MEC.
Source: ASCO Abstract 11006
Indication: Patients on chemotherapy/surgery
Key finding: ePRO use vs non-use: 12-mo OS chemo 76.8% vs 66.6% (HR 0.63, 95% CI 0.57–0.69); surgery 96.0% vs 93.3% (HR 0.58).
Clinical relevance: Routine ePRO use is associated with better survival.
Source: ASCO Abstract 11003
Indication: Solid + hematologic malignancies on ICI
Key finding: 3-yr mortality HR 0.69 (95% CI 0.64–0.75); 5-yr HR 0.71; reduced pyrexia (OR 0.73).
Clinical relevance: A hypothesis-generating association between GLP-1 RA use and ICI outcomes.
Source: ASCO Abstract 11000
Indication: CAR-T recipients
Key finding: 3-yr mortality HR 0.61 (95% CI 0.41–0.90); higher CRS grade 1/2 (OR 1.58); ICANS unchanged.
Clinical relevance: An association of mRNA vaccination with improved survival in CAR-T recipients.
Source: ASCO Abstract 11001
Indication: Patients on ADC/BiTE/CAR-T
Key finding: Mortality HR vs mFI-5=0: 1.41 (mFI=1), 1.79 (mFI=2), 2.45 (mFI=3), 2.51 (mFI=4+).
Clinical relevance: Frailty index predicts mortality in patients receiving novel therapies.
Source: ASCO Abstract 11002
Indication: Patients on systemic therapy
Key finding: Hospitalization 9.0% (RTM) vs 13% (control); risk difference −3.63 (95% CI −7.06 to −0.39, p=0.032); ED visits 12% vs 13% (p=0.310).
Clinical relevance: RTM reduces hospitalizations.
Source: ASCO Abstract 11005
Indication: Hereditary cancer family cascade testing
Key finding: Registry-aided outreach increased pre-test counseling 39.8% vs 20.0% and cascade testing 36.2% vs 19.5%.
Clinical relevance: Proactive outreach roughly doubles cascade-testing uptake.
Source: ASCO Abstract 11007
Indication: Young-onset colorectal cancer (YOCRC)
Key finding: Multidimensional service utilization 72.5% vs 44.7% (p<0.001); aOR 1.48 (95% CI 1.22–1.80).
Clinical relevance: A dedicated coordinator improves supportive-service uptake.
Source: ASCO Abstract 11008
Indication: Patients on systemic therapy (Japan)
Key finding: No global health status improvement (Δ −0.61, p=0.625); OS HR 0.91 (p=0.240); terminated early for futility.
Clinical relevance: Not all ePRO implementations replicate prior survival benefits.
Source: ASCO Abstract 11004
Indication: AI use in oncology practice and education
Key finding: Cross-sectional surveys; descriptive findings only, without comparative outcome data.
Clinical relevance: Snapshot of adoption attitudes; not outcome-defining.
Source: ASCO Abstracts 9000–9002
This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.
OncoHub.ai · ASCO 2026 Gündem
Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir.
oncohub.ai →